… (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (COVID-19) …
safety of sarilumab, an anti–IL-6R monoclonal antibody, in the treatment of hospitalized patients …

… or sarilumab may improve clinical outcomes in patients with Covid-19, … safety of intravenous
(IV) sarilumab, an anti–IL-6R monoclonal antibody, for the treatment of hospitalized patients …

… the role of sarilumab. In this review, we aim to analyze the role of the … , sarilumab, in the
treatment of COVID-19 patients. … Sarilumab may reduce the number of days of hospitalization. …

Objective The objective of this study was to evaluate the long-term safety and efficacy of
sarilumab over 5 years in patients with RA refractory to TNF inhibitors (TNFis). Methods Patients …

… AEs that required inpatient hospitalization or prolongation of existing hospitalization) and …
Serious infections were defined as infections requiring hospitalization and/or intravenous …

… Long-term sarilumab treatment with/without csDMARDs in patients with RA revealed no
new safety findings. Efficacy and HRQOL were maintained or further increased over the open-…

… We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, in
patients with severe (requiring supplemental oxygen by nasal cannula or face mask) or critical …

… safety of early treatment with sarilumab, added to standard of care (SOC), in hospitalized …
, randomized, controlled clinical trial of hospitalized patients with COVID-19 pneumonia and …

… the efficacy and safety of the administration of two doses of sarilumab (200 … safety will be
monitored up to 28 days postadministration. A total of 120 patients will be recruited (40 patients …

… with sarilumab … patients with interstitial pneumonia. This study will also provide supportive
evidence to that provided by currently ongoing studies on the efficacy and safety of sarilumab …